AbSci, a Portland, Oregon-based provider of soluble microbial protein expression technology, secured $5.1m in Series A financing.
The round was led by Phoenix Venture Partners. In conjunction with the funding, Dr. Zach Jonasson, General Partner at PVP, will be joining AbSci’s Board of Directors.
The company intends to use the funds to support further development and scale-up of SoluPro™ for commercial production of insulin and other therapeutic proteins.
Led by Sean McClain, Founder and CEO, AbSci provides the SoluPro™ platform which enables higher protein yields in less time than current processes to accelerate drug discovery timelines, increase manufacturing efficiencies, and reduce costs for the biopharmaceutical industry.